Meghan Trainor Stuns At TV Premiere After 31 Kg Weight Loss, Admits Using Weight Loss Drug

  //health-fitness.news-articles.net/co .. ss-admits-using-weight-loss-drug.html
  Published in Health and Fitness on Fri, Aug 8th, 2025

Meghan Trainor’s 31‑kilogram Weight Loss: The Celebrity’s Confession and the Role of Mounjaro

The pop icon Meghan Trainor, best known for her hit “All About That Bass,” stunned fans at a recent television premiere after shedding an impressive 31 kg (about 68 lb). While the star had previously attributed her transformation to a strict diet and rigorous workout routine, she has now come forward to admit that she also used the prescription weight‑loss drug Mounjaro (tirzepatide) to reach her goal. The revelation comes as she appears on a new TV special celebrating her latest album and her personal journey, bringing a fresh lens to the public debate over “miracle” medications and the pressures of celebrity wellness.

From the Big Stage to a Smaller Stage

Trainor’s weight‑loss story began on the back‑stage area of the recording studio, where she confessed in a candid interview with The Health Site that the singer had struggled for years to maintain a “healthy” body. The new TV premiere, a one‑hour special titled Meghan Trainor: The Journey, aired on a streaming platform and was filmed at the singer’s Los Angeles home. The program offers an intimate look at her daily routine—early‑morning cardio, vegan meals, and mental‑health practices—while juxtaposing clips from her earlier music videos that flaunted a fuller figure.

During the premiere, Trainor introduced a “before and after” montage that featured a series of photographs taken over the past 18 months. She explained that the photos illustrate the scale of her progress and were part of the “show’s” promotional materials. Her appearance also included a live performance of her new single, which she says “reminds me that I’m still a songwriter at heart.”

The Weight‑Loss Drug That Made Headlines

The highlight of the interview was Trainor’s disclosure that she had taken Mounjaro (tirzepatide) for the past several months as part of her weight‑loss regimen. Mounjaro is a glucagon‑like peptide‑1 (GLP‑1) agonist that was originally approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes. The drug has, however, attracted attention in the weight‑loss arena because it has shown promising results in clinical trials that demonstrate significant reductions in body mass.

According to the interview, Trainor received a prescription from a medical provider who advised her that the drug could be a “game‑changer” for her case. She noted that the medication is administered as a once‑weekly injection and that it “worked in tandem with my diet and exercise plan.” She also mentioned that she used a specific dosage that the doctor determined would best suit her body weight and health status.

How Mounjaro Works

The drug’s mechanism revolves around mimicking the body’s natural hormones that regulate appetite and insulin. When used in combination with lifestyle changes, it has shown weight loss percentages ranging from 12 % to 15 % over 68 weeks in large clinical trials. The study data is published in the New England Journal of Medicine and has attracted attention from both medical professionals and celebrities seeking to address obesity.

In the interview, Trainor said she experienced typical side effects such as nausea, diarrhea, and mild injection‑site discomfort. She added that the side‑effect profile was manageable because she received guidance from her healthcare team. She also stressed the importance of regular medical supervision when using the medication, noting that it “should not be used by anyone without a doctor’s oversight.”

The Cost and Accessibility

One aspect of Mounjaro that has garnered scrutiny is its cost. At a retail price of $1,800–$2,200 per month in the United States, the drug remains a luxury item for most. Trainor’s own account indicates that she covered the cost through a combination of her own savings and an insurance plan that partially covered the medication. She explained that the high price has contributed to the perception that weight‑loss treatments are only for the wealthy, which is why she said it was “important to talk openly about it.”

Industry analysts predict that the price may drop if competition emerges in the GLP‑1 agonist market. Several pharmaceutical companies have announced new drug candidates that might rival Mounjaro in the coming years, potentially making the treatment more accessible.

The Broader Conversation: Celebrity Wellness and Public Perception

Trainor’s openness has sparked a broader conversation about the role of prescription medications in celebrity health. While she framed her use of Mounjaro as an “additive” to her existing lifestyle changes, some observers argue that it raises ethical questions about the influence of celebrities on public expectations regarding weight loss. In an interview with The Health Site, the singer acknowledged that she does not intend to “encourage anyone to start a drug” but hopes that her story might help others who feel stuck.

“Everyone should go to a doctor and see what’s best for them,” Trainor said. “It’s not about making a quick fix; it’s about the journey and making sustainable changes.”

Takeaway

Meghan Trainor’s journey to a 31‑kg weight loss and her candid admission of using Mounjaro bring a multifaceted lens to the conversation around celebrity health and the evolving landscape of prescription weight‑loss treatments. By juxtaposing her own experience with the clinical data and cost realities of the drug, Trainor provides an honest glimpse into the challenges and triumphs of navigating a wellness path under public scrutiny. Whether the public embraces her candidness as an empowering call to action or critiques it as a glamorized use of medication, the conversation is unmistakably moving forward.